Showing 742 results
-
Press release /Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…
-
Press release /European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Press release /Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
-
Press release /Diabetic macular edema (DME) is a leading cause of blindness in adults in developed countries; unmet needs in DME include improving fluid resolution in the retina and addressing the burden of…
-
Press release /
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a… -
Ad hoc release /EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would…
-
Story /Accelerating Research to Get Answers Faster
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
-
Press release /European Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for…
-
Press release /Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…